Benchmarking AMN Healthcare Services (NYSE:AMN)

Benchmarking AMN Healthcare Services (NYSE:AMN)

Benchmarking AMN Healthcare Services (NYSE:AMN)

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at AMN Healthcare Services (NYSE:AMN) and its peers.

The healthcare providers and services sector, from insurers to hospitals, benefits from consistent demand, generating stable revenue through premiums and patient services. However, it faces challenges from high operational and labor costs, reimbursement pressures that squeeze margins, and regulatory uncertainty. Looking ahead, an aging population with more chronic diseases and a shift toward value-based care create tailwinds. Digitization via telehealth, data analytics, and personalized medicine offers new revenue streams. Nonetheless, headwinds persist, including clinical labor shortages, ongoing reimbursement cuts, and regulatory scrutiny over pricing and quality.

The 40 healthcare providers & services stocks we track reported a strong Q3. As a group, revenues beat analysts’ consensus estimates by 2.3% while next quarter’s revenue guidance was 0.6% below.

In light of this news, share prices of the companies have held steady as they are up 4.4% on average since the latest earnings results.

With a network of thousands of healthcare professionals ranging from nurses to physicians to executives, AMN Healthcare (NYSE:AMN) provides healthcare workforce solutions including temporary staffing, permanent placement, and technology platforms for hospitals and healthcare facilities across the United States.

AMN Healthcare Services reported revenues of $634.5 million, down 7.7% year on year. This print exceeded analysts’ expectations by 2.7%. Overall, it was an exceptional quarter for the company with a beat of analysts’ EPS estimates and revenue guidance for next quarter exceeding analysts’ expectations.

“The AMN team responded impressively to the second quarter’s marketplace uncertainty, delivering third quarter revenue and earnings ahead of our guidance,” said Cary Grace, President and Chief Executive Officer of AMN Healthcare.

AMN Healthcare Services Total Revenue
AMN Healthcare Services Total Revenue

AMN Healthcare Services delivered the slowest revenue growth of the whole group. Unsurprisingly, the stock is down 10.9% since reporting and currently trades at $16.42.

Is now the time to buy AMN Healthcare Services? Access our full analysis of the earnings results here, it’s free for active Edge members.

Pioneering the field of “liquid biopsy” with technology that can identify cancer-specific genetic mutations from a simple blood draw, Guardant Health (NASDAQ:GH) develops blood tests that detect and monitor cancer by analyzing tumor DNA in the bloodstream, helping doctors make treatment decisions without invasive biopsies.

Leave a Comment

Your email address will not be published. Required fields are marked *